Unum Therapeutics completed the acquisition of Kiq.

Unum Therapeutics, a biopharmaceutical company focused on developing therapies for solid tumors, completed the acquisition of Kiq, a privately held, biotechnology company focused on the discovery and development of precision kinase inhibitors. The acquisition of Kiq was structured as a stock-for-stock transaction whereby all of Kiq's outstanding equity interests were exchanged for a combination of shares of Unum common stock and shares Series A preferred stock. "Unum has explored a range of strategic alternatives through an orderly process to maximize shareholder value, and we believe this acquisition represents the highest-potential value creation opportunity for Unum stockholders. We are excited by Kiq's lead clinical program and the potential to build a pipeline of novel kinase inhibitors while continuing to explore strategic opportunities for our cell-based therapy programs. As the science develops, we will continue to drive forward our mission of developing novel, best-in-class therapeutics for patients with the greatest need, and we thank our Board members, past and present, along with our investors for their support and commitment," Chuck Wilson, Unum President and CEO.